These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 32302411)

  • 61. Azithromycin in viral infections.
    Oliver ME; Hinks TSC
    Rev Med Virol; 2021 Mar; 31(2):e2163. PubMed ID: 32969125
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Local Delivery of Azithromycin Nanoformulation Attenuated Acute Lung Injury in Mice.
    Alrashedi MG; Ali AS; Ahmed OA; Ibrahim IM
    Molecules; 2022 Nov; 27(23):. PubMed ID: 36500388
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID-19 Clinical Trials.
    Hughes JH; Sweeney K; Ahadieh S; Ouellet D
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):435-443. PubMed ID: 32511867
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rationale for azithromycin in COVID-19: an overview of existing evidence.
    Gyselinck I; Janssens W; Verhamme P; Vos R
    BMJ Open Respir Res; 2021 Jan; 8(1):. PubMed ID: 33441373
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness of Azithromycin as Add-on Therapy in COVID-19 Management.
    Wahab S; Ahmad MF; Hussain A; Usmani S; Shoaib A; Ahmad W
    Mini Rev Med Chem; 2021; 21(19):2860-2873. PubMed ID: 33797374
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reduction of Coronavirus Burden With Mass Azithromycin Distribution.
    Doan T; Hinterwirth A; Arzika AM; Worden L; Chen C; Zhong L; Oldenburg CE; Keenan JD; Lietman TM
    Clin Infect Dis; 2020 Nov; 71(16):2282-2284. PubMed ID: 32426812
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19.
    Ali AS; ASattar MA; Karim S; Kutbi D; Aljohani H; Bakhshwin D; Alsieni M; Alkreathy HM
    Arab J Chem; 2021 Mar; 14(3):102983. PubMed ID: 34909062
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Poly(sebacic acid) microparticles loaded with azithromycin as potential pulmonary drug delivery system: Physicochemical properties, antibacterial behavior, and cytocompatibility studies.
    Knap K; Reczyńska-Kolman K; Kwiecień K; Niewolik D; Płonka J; Ochońska D; Jeleń P; Mielczarek P; Kazek-Kęsik A; Jaszcz K; Brzychczy-Włoch M; Pamuła E
    Biomater Adv; 2023 Oct; 153():213540. PubMed ID: 37429048
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
    Pani A; Lauriola M; Romandini A; Scaglione F
    Int J Antimicrob Agents; 2020 Aug; 56(2):106053. PubMed ID: 32534189
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
    Arshad S; Kilgore P; Chaudhry ZS; Jacobsen G; Wang DD; Huitsing K; Brar I; Alangaden GJ; Ramesh MS; McKinnon JE; O'Neill W; Zervos M;
    Int J Infect Dis; 2020 Aug; 97():396-403. PubMed ID: 32623082
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
    Sultana J; Cutroneo PM; Crisafulli S; Puglisi G; Caramori G; Trifirò G
    Drug Saf; 2020 Aug; 43(8):691-698. PubMed ID: 32696429
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
    Rosenberg ES; Dufort EM; Udo T; Wilberschied LA; Kumar J; Tesoriero J; Weinberg P; Kirkwood J; Muse A; DeHovitz J; Blog DS; Hutton B; Holtgrave DR; Zucker HA
    JAMA; 2020 Jun; 323(24):2493-2502. PubMed ID: 32392282
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.
    Choudhary R; Sharma AK
    New Microbes New Infect; 2020 May; 35():100684. PubMed ID: 32322397
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment options for COVID-19: The reality and challenges.
    Jean SS; Lee PI; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Should azithromycin be used to treat COVID-19? A rapid review.
    Gbinigie K; Frie K
    BJGP Open; 2020; 4(2):. PubMed ID: 32398343
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
    Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management.
    Kelleni MT
    Pharmacol Res; 2020 Jul; 157():104874. PubMed ID: 32360581
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
    Cavalcanti AB; Zampieri FG; Rosa RG; Azevedo LCP; Veiga VC; Avezum A; Damiani LP; Marcadenti A; Kawano-Dourado L; Lisboa T; Junqueira DLM; de Barros E Silva PGM; Tramujas L; Abreu-Silva EO; Laranjeira LN; Soares AT; Echenique LS; Pereira AJ; Freitas FGR; Gebara OCE; Dantas VCS; Furtado RHM; Milan EP; Golin NA; Cardoso FF; Maia IS; Hoffmann Filho CR; Kormann APM; Amazonas RB; Bocchi de Oliveira MF; Serpa-Neto A; Falavigna M; Lopes RD; Machado FR; Berwanger O;
    N Engl J Med; 2020 Nov; 383(21):2041-2052. PubMed ID: 32706953
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Azithromycin in the treatment of COVID-19: a review.
    Echeverría-Esnal D; Martin-Ontiyuelo C; Navarrete-Rouco ME; De-Antonio Cuscó M; Ferrández O; Horcajada JP; Grau S
    Expert Rev Anti Infect Ther; 2021 Feb; 19(2):147-163. PubMed ID: 32853038
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
    Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F
    Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.